AZT Stock Overview
A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 13.30 |
| 52 Week High | NOK 43.20 |
| 52 Week Low | NOK 12.60 |
| Beta | 0.97 |
| 11 Month Change | -22.04% |
| 3 Month Change | -36.67% |
| 1 Year Change | -66.96% |
| 33 Year Change | -85.30% |
| 5 Year Change | 177.08% |
| Change since IPO | -46.80% |
Recent News & Updates
Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Nov 12
ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Nov 09Recent updates
Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Nov 12ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Nov 09The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
Aug 31ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
Aug 30ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 25Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
May 12ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 08ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
Feb 02ArcticZymes Technologies ASA's (OB:AZT) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Apr 29Downgrade: Here's How This Analyst Sees ArcticZymes Technologies ASA (OB:AZT) Performing In The Near Term
Apr 15One Analyst Just Shaved Their ArcticZymes Technologies ASA (OB:AZT) Forecasts Dramatically
Jan 13Here's What Analysts Are Forecasting For ArcticZymes Technologies ASA (OB:AZT) After Its First-Quarter Results
May 01What ArcticZymes Technologies ASA's (OB:AZT) P/E Is Not Telling You
Oct 28A Look At The Fair Value Of ArcticZymes Technologies ASA (OB:AZT)
Jul 26I Ran A Stock Scan For Earnings Growth And ArcticZymes Technologies (OB:AZT) Passed With Ease
Apr 28Shareholder Returns
| AZT | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -2.5% | 16.2% | 2.2% |
| 1Y | -67.0% | -67.2% | 3.3% |
Return vs Industry: AZT matched the Norwegian Biotechs industry which returned -67.2% over the past year.
Return vs Market: AZT underperformed the Norwegian Market which returned 3.3% over the past year.
Price Volatility
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: AZT's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: AZT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 53 | Michael Akoh | www.arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets.
ArcticZymes Technologies ASA Fundamentals Summary
| AZT fundamental statistics | |
|---|---|
| Market cap | NOK 679.25m |
| Earnings (TTM) | NOK 4.63m |
| Revenue (TTM) | NOK 110.76m |
146.8x
P/E Ratio6.1x
P/S RatioIs AZT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZT income statement (TTM) | |
|---|---|
| Revenue | NOK 110.76m |
| Cost of Revenue | NOK 6.50m |
| Gross Profit | NOK 104.26m |
| Other Expenses | NOK 99.64m |
| Earnings | NOK 4.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.091 |
| Gross Margin | 94.13% |
| Net Profit Margin | 4.18% |
| Debt/Equity Ratio | 0% |
How did AZT perform over the long term?
See historical performance and comparison